Intraperitoneal antineoplastic drug delivery: experience with a cyclophosphamide, vincristine and prednisolone protocol in cats with malignant lymphoma.
Teske, Erik; van Lankveld, A. J.; Rutteman, G. R.
2014 • In Veterinary and Comparative Oncology, 12 (1), p. 37-46
[en] In this retrospective study, the efficacy and safety were examined for an intraperitoneal chemotherapy protocol-cyclophosphamide, vincristine and prednisolone (IP-COP) in 26 cats with malignant lymphoma. Certainly in cats fiercely resisting IV administration the IP route is a more practical method, safer for the administrator and less stressful for the cat. Complete remission (CR) rate was 76.9% (n = 20). Median duration of first remission was 421 days. Estimated 1- and 2-year disease free period were 67.1 and 48.0%, respectively. Median duration of survival was 388 days and estimated overall 1- and 2-year survival periods were 54.7 and 46.9% respectively. Young cats had a more favourable prognosis. Reaching CR was essential for long-term survival. No specific IP-related adverse events (AE) were seen. AE were generally scored as mild and were not excessively abundant. These results indicate that the IP route is a safe and effective alternative for the administration of COP protocol chemotherapeutics.
Disciplines :
Veterinary medicine & animal health
Author, co-author :
Teske, Erik ; Université de Liège - ULiège > Dép. clinique des animaux de compagnie et des équidés (DCA) > Dép. clinique des animaux de compagnie et des équidés (DCA)
van Lankveld, A. J.
Rutteman, G. R.
Language :
English
Title :
Intraperitoneal antineoplastic drug delivery: experience with a cyclophosphamide, vincristine and prednisolone protocol in cats with malignant lymphoma.
Teske E, van Straten G, van Noort R and Rutteman GR. Chemotherapy with cyclophosphamide, vincristine, and prednisolone (COP) in cats with malignant lymphoma: New results with an old protocol. Journal of Veterinary Internal Medicine 2002; 16: 179-186.
Louwerens M, London CA, Pedersen NC and Lyons LA. Feline lymphoma in the post-feline leukemia virus era. Journal of Veterinary Internal Medicine 2005; 19: 329-335.
Hayes A. Feline lymphoma 1. Principles of diagnosis and management. In Practice 2006; 28: 516-524.
Malik R, Gabor LJ and Canfield PJ. Lymphoma in Australian cats-lessons for Europe? Journal of Feline Medicine and Surgery 2003; 5: 147-150.
Ettinger SN. Principles of treatment for feline lymphoma. Clinical Techniques in Small Animal Practice 2003; 18: 98-102.
Vail DM, Moore AS, Ogilvie GK and Volk LM. Feline lymphoma (145 cases): proliferation indices, cluster of differentiation 3 immunoreactivity, and their association with prognosis in 90 cats. Journal of Veterinary Internal Medicine 1998; 12: 349-354.
Simon D, Eberle N, Laacke-Singer L and Nolte I. Combination chemotherapy in feline lymphoma: treatment outcome, tolerability, and duration in 23 cats. Journal of Veterinary Internal Medicine 2008; 22: 394-400.
Cotter SM. Treatment of lymphoma and leukemia with cyclophosphamide, vincristine and prednisolone: II. Treatment of cats. Journal of the American Animal Hospital Association 1983; 19: 166-172.
Los G, Mutsaers PHA, van der Vijgh WJF, Baldew GS, de Graaf PW and MeVie JG. Direct diffusion of cfV diamminedichloroplatinum (II) in intraperitoneal rat tumors after intraperitonal chemotherapy: a comparison with systemic chemotherapy. Cancer Research 1989; 49: 3380-3384.
Markman M. Intraperitoneal chemotherapy. Critical Reviews in Oncology: Hematology 1999; 31: 239-246.
VCOG. Veterinary Co-Operative Oncology Group-common terminology criteria for adverse events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats. Veterinary Comparative Oncology 2004; 2: 194-213.
Markman M. Intraperitoneal antineoplastic drug delivery: rationale and results. The Lancelet Oncology 2003; 4: 277-283.
Markman M. Intraperitoneal chemotherapy. In: Perry MC (ed). The chemotherapy source book. 4th ed. Philadelphia, PA, Lippincott Wilkins & Williams. 2007:75-77.
Miyagi Y, Fujiwara K, Kigawa J, Itamochi H, Nagao S, Aotani E, Terakawa N, Kohno I and Sankai Gynecology Study Group (SGSG). Intraperitoneal carboplatin infusion may be a pharmacologically more reasonable route than intravenous administration as a systemic chemotherapy. A comparative pharmacokinetic analysis of platinum using a new mathematical model after intraperitoneal vs. intravenous infusion of carboplatin - a Sankai Gynecology Study Group (SGSG) study. Gynecologic Oncology 2005; 99: 591-596.
Gabor LJ, Jackson ML, Trask B, Malik R and Canfield PJ. Feline leukemia virus status of Australian cats with lymphosarcoma. Australian Veterinary Journal 2001; 79: 476-481.
Milner RJ, Peyton J, Cooke K, Fox LE, Gallagher A, Gordon P and Hester J. Response rates and survival times for cats with lymphoma treated with the University of Wisconsin-Madison chemotherapy protocol: 38 cases (1996-2003). Journal of the American Veterinary Medical Association 2005; 7: 1118-1122.
Court EA, Watson AD and Peaston AE. Retrospective study of 60 cases of feline lymphosarcoma. Australian Veterinary Journal 1997; 6: 424-427.
Mooney SC, Hayes AA, MacEwen EG, Matus RE, Geary A and Shurgot BA. Treatment and prognostic factors in lymphoma in cats: 103 cases (1977-1981). Journal of the American Veterinary Medical Association 1989; 194: 349-354.
Stützer B, Simon K, Lutz H, Majzoub M, Hermanns W, Hirschberger J, Sauter-Louis C and Hartmann K. Incidence of persistent viraemia and latent feline leukaemia virus infection in cats with lymphoma. Journal of Feline Medicine and Surgery 2011; 13: 81-87.
Moore AS, Cotter SM, Frimberger AE, Wood CA, Rand WM and L'Heureux DA. A comparison of doxorubicin and COP for maintenance of remission in cats with lymphoma. Journal of Veterinary Internal Medicine 1996; 10: 372-375.
Kristal O, Lana SE, Ogilvie GK, Rand WM, Cotter SM and Moore AS. Single agent chemotherapy with doxorubicin for feline lymphoma: a retrospective study of 19 cases (1994-1997). Journal of Veterinary Internal Medicine 2001; 15: 125-130.
Patterson-Kane JC, Perrins Kugler B and Francis K. The possible prognostic significance of immunophenotype in feline alimentary lymphoma: a pilot study. Journal of Comparative Pathology 2004; 130: 220-222.
Gabor LJ, Canfield PJ and Malik R. Immunophenotypic and histological characterization of 109 cases of feline lymphosarcoma. Australian Veterinary Journal 1999; 77: 436-441.
Piek CJ, Rutteman GR and Teske E. Evaluation of the results of a L-asparaginase-based continuous chemotherapy protocol versus a short doxorubicin-based induction chemotherapy protocol in dogs with malignant lymphoma. Veterinary Quarterly 1999; 21: 44-49.
Tzannes S, Hammond MF, Murphy S, Sparkes A and Blackwood L. Owners 'perception of their cats' quality of life during COP chemotherapy for lymphoma. Journal of Feline Medicine and Surgery 2008; 10: 73-81.
Brønden LB, Rutteman GR, Flagstad A and Teske E. Study of dog and cat owners' perceptions of medical treatment for cancer. Veterinary Record 2003; 152: 77-80.
ECVIM-CA. Preventing Occupational and Environmental Exposure to Cytotoxic Drugs in Veterinary Medicine, 2nd edn., 2007. http://www.ecvim-ca.org/index.php?option=com_content&view=article&id=72&Itemid=70 [accessed 11 March 2012].